Patients considering GLP-1 receptor agonist or dual GIP/GLP-1 therapy should understand that these medications facilitate weight loss through appetite reduction and decreased food intake, not by "speeding up metabolism" or burning additional calories at rest
European Medicines Agency (EMA) Eli Lilly typically files for European approval (through the EMA's centralized procedure) around the same time as the FDA submission, sometimes within a few months
However, diabetes (49% vs 14%) and hypertension (57% vs 38%) were more common in the treatment group
This supplement supports energy metabolism, aids in stress reduction, and promotes a healthy immune system
There were several changes made in the clinic during 2024 to improve the prescription process, according to Ngyuen
Food and Drug Administration (FDA) for use by the general public